Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.32
-0.07 (-0.83%)
At close: Jun 12, 2026, 4:00 PM EDT
8.00
-0.32 (-3.85%)
After-hours: Jun 12, 2026, 7:59 PM EDT
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $156.10M in the quarter ending March 31, 2026, a decrease of -29.75%. This brings the company's revenue in the last twelve months to $676.80M, down -29.89% year-over-year. In the year 2025, Emergent BioSolutions had annual revenue of $742.90M, down -28.81%.
Revenue (ttm)
$676.80M
Revenue Growth
-29.89%
P/S Ratio
0.63
Revenue / Employee
$752,000
Employees
900
Market Cap
429.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 742.90M | -300.70M | -28.81% |
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
| Dec 31, 2018 | 782.40M | 221.50M | 39.49% |
| Dec 31, 2017 | 560.90M | 72.10M | 14.75% |
| Dec 31, 2016 | 488.80M | -531.00K | -0.11% |
| Dec 31, 2015 | 489.33M | 84.87M | 20.98% |
| Dec 31, 2014 | 404.47M | 91.72M | 29.33% |
| Dec 31, 2013 | 312.75M | 30.86M | 10.95% |
| Dec 31, 2012 | 281.89M | 8.50M | 3.11% |
| Dec 31, 2011 | 273.38M | -12.79M | -4.47% |
| Dec 31, 2010 | 286.17M | 51.39M | 21.89% |
| Dec 31, 2009 | 234.79M | 56.23M | 31.49% |
| Dec 31, 2008 | 178.55M | -4.36M | -2.38% |
| Dec 31, 2007 | 182.92M | 30.18M | 19.76% |
| Dec 31, 2006 | 152.73M | 22.04M | 16.87% |
| Dec 31, 2005 | 130.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 858.28M |
| Organogenesis Holdings | 514.70M |
| Ironwood Pharmaceuticals | 361.51M |
| Evolus | 301.79M |
| Akebia Therapeutics | 232.40M |
| Canopy Growth | 203.04M |
| Kamada | 181.68M |
| SIGA Technologies | 93.78M |
EBS News
- 6 days ago - Emergent BioSolutions Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 10 days ago - Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose - GlobeNewsWire
- 11 days ago - Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Emergent BioSolutions awarded $64.5M HHS contract modification - TheFly
- 17 days ago - Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy - GlobeNewsWire
- 25 days ago - Emergent BioSolutions to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Emergent BioSolutions receives Saudi approval for ACAM2000 vaccine - TheFly
- 27 days ago - Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] - GlobeNewsWire